DIFFERENCES IN INNATE IMMUNE RESPONSE BETWEEN MAN AND MOUSE

Josefin Zscherler 1,2,*, Denise Schlorke 1,2,* & Juergen Arnhold 1,2

1 Institute for Medical Physics and Biophysics, Medical Faculty, Leipzig University, Leipzig, Germany
2 Translational Centre for Regenerative Medicine (TRM), Leipzig University, Leipzig, Germany
* Both authors contributed equally to this work.

Abstract

Mouse strains are frequently used to model human disease states, to test the efficiency of drugs and therapeutic principles. However, the direct translation of murine experimental data to human pathological events often fails due to sufficient differences in the organization of the immune system of both species. Here we give a short overview of the principle differences between mice and humans in defense strategies against pathogens and mechanisms involved in response to pathogenic microorganisms and other activators of the immune system. While in human blood mechanisms of immune resistance are highly prevailed, tolerance mechanisms dominate for the defense against pathogenic microorganisms in mouse blood. Further on, species-related differences of immune cells mainly involved in innate immune response as well as differences to maintain oxidative homeostasis are also considered. A number of disease scenarios in mice are critically reflected for their suitability to serve as a model for human pathologies. Due to setbacks in these studies, novel mouse models were created to bridge the immune system of both species: humanized mice. Accordingly, a special section of this review is devoted to new results applying humanized mouse models taking limitations and prospects into account.

Abbreviations

BPI: bactericidal/permeability-increasing protein; CD: cluster of differentiation; FPR: formyl peptide receptor; HLA: human leukocyte antigen; HNP: human neutrophil peptide; HSC: human stem cells; IDO: indoleamine-2,3-dioxygenase; IFN: interferon; IL: interleukin; IL2ry:
interleukin 2 receptor gamma; **iNOS**: inducible nitric oxide synthase; **IRG**: p47 immunity-related GTPase; **LPS**: lipopolysaccharide; **MHC**: major histocompatibility complex; **MPO**: myeloperoxidase; **RAG**: recombination-activating gene; **TLR**: Toll-like receptor; **TNFα**: tumor necrosis factor α

**Keywords**

innate immunity, leukocytes, mouse model, resistance, tolerance

I. INTRODUCTION

In humans, pathogens, traumata, and antigens can activate cells of the innate and in many cases also of the adaptive immune system. Immune cell activation contributes to neutralization and elimination of the initiating agents and is directed to abolish any harm from the host. However, immune stimulation results sometimes in long-lasting inflammatory events and disease states. Finding an adequate and person-specific therapy for such pathological scenarios is a great challenge for physicians and researchers. Laboratory mouse strains are widely used to test drugs and to develop novel therapeutic strategies on artificially induced diseases.

It is quite obvious that man and mouse are different in respect to their size, behavior, lifespan, living conditions, ecological niches, and other properties. Nevertheless, the leading model system for biomedical research is the mouse. Almost 100 years ago, malting programs established in the Jackson Laboratory created the first inbred mouse strains used for cancer research. Today, various modern mouse strains are used in laboratories worldwide to test drugs in disease models because of their short lifetime, easy reproduction, comparable low costs, public acceptance, ease of genetic manipulation, and the possibility to keep them under standardized conditions.

Undoubtedly, detailed investigations of similar molecular pathways in mice considerably increased our knowledge about the corresponding immune reactions in humans. For example, elucidation of signaling via toll-like receptor 4 in mouse strains provided important useful information about basic mechanisms in human innate immunity. It is also evident that in some murine models of human diseases, an identical point mutation is responsible for the development of the same disease phenotype in both species as in the pathogenesis of the Burkitt lymphoma or in leukocyte adhesion defect syndromes.

Despite these and other commonalities, adequate translation of results from animal experiments to humans is often highly challenging, frustrating, and in many cases very unsuccessful. Several items have been summarized that make the mouse to an improper model for human diseases. These constraints are the use of inbred mice strains that may have homozygous recessive defects, application of disease protocols that are often far from reality, large evolutionary distance between both species, and differences in organization of the immune system. For example, the Mx1 gene, which provides resistance to influenza virus infection, is deleted in most standard laboratory inbred mouse strains. Mouse strains originating from wild mice uniformly carry the Mx1 gene. The most serious problem in translation of mouse model data to human diseases is that man and mouse developed divergent strategies during evolution to combat infections, which result in a different management of the accompanying inflammatory process.

As it is impossible to cover all immunologically relevant differences between both species, this review focuses on the basic differences in the organization of immune responses and
the differences among cells of the innate immune system, as well as the critical reflection of disease models.

II. THE MOUSE GENOME IN COMPARISON TO MAN

A. General Genome Properties

Modern genetic approaches allow detailed analysis of genomes in, inter alia, man and mouse. Due to a common precursor of both species, substantial amounts of orthologous genes are found together with a sufficient number of species-relevant individual genes. The first mouse genome sequence was published in 2002. Improved methodological approaches led to publication of a refined version of the mouse genome in 2009. All data given here are referred to this second version.

Novel improved sequencing approaches revealed that the number of genes in mouse is 20,210, while humans have only 19,042 genes (see also Table 1). There are 15,187 genes of both species that are functionally closely related, indicating their existence in an ancient common precursor species living about 90 million years ago as rodent and primate lines were separating. That means 75% of mouse genes and 80% of human genes are orthologs. These one-to-one orthologs exhibit median nucleotide and amino acid identities of 85.3% and 88.2%, respectively.

Interestingly, the number of duplicated genes is higher in mouse than in man (3767 versus 2941). In mice, duplicated genes encode mostly olfactory and vomeronasal functions, pheromone senses, or are associated with reproductive functions, for instance, with processes during spermatogenesis.

B. Essential and Nonessential Orthologous Genes

Another study compared orthologs of essential genes in humans and mice. A total of 1716 human genes were identified as genes with a clear disease-related association. Of this group 1450 genes have one-to-one orthologs in the mice genome. From this gene pool, 120 human genes were selected as essential genes, implying that deletions of these human genes are associated with early death (before puberty) or infertility. Proof of essentiality of these genes in mice revealed that 27 genes were nonessential and 93 genes were essential. The criterion for essentiality in mice was death before reproductive age or infertility in the corresponding knockout animal.

Twelve of 27 nonessential genes in mouse are related to degradation of cellular waste and toxins within lysosomes. Comparison between metabolic rates revealed that humans produce about 18 times more waste products until they reach the reproductive age, than mice, per unit of body mass. Hence, diseases concerning waste management are more important in human beings than in mice. In mice, there is a tendency for the development of such diseases at more advanced age of life. Consequently, knowledge of human diseases gained from mouse models is only basic, but will not yield sufficiently accurate information. This especially holds for neurologic diseases associated with defective waste product elimination.

III. RESISTANCE VERSUS TOLERANCE

A. Main Immunological Defense Principles

Survival of a species depends not only on numerous adaptations to environmental conditions but is also determined by a well-functioning immune system. The latter is
responsible for recognition and elimination of pathogens as well as different self- and environmental antigens, and to hold any threat at a low extent to the whole organism coming from these agents.

Two general principal mechanisms exist to combat deleterious pathogens and antigens, resistance, and tolerance. Resistance mechanisms are directed to deactivate and eliminate unwanted microbes and other pathogens as early as possible. Thus, a number of fine mechanisms exist for activation of host immune cells after recognition of specific pathogen markers. This immune activation keeps the number of invading pathogens at a low level.

In contrast, tolerance mechanisms are developed to hold any threat to the host at a low level coming from pathogens although they might be present in a high number in some host compartments. Thus, tolerance ensures survival of host cells and tissues as well as host functioning despite a high load of pathogens. However, host protecting mechanisms should exist to hold the total number of pathogens below a given—for the host tolerable—threshold.

Considering systemic effects of the immune defense organization, in humans resistance mechanisms dominate, while in mice tolerance mechanisms are highly prevailed. During the last 30 years, immunologists focused mainly on investigating and understanding resistance despite exploring tolerance mechanisms. Although a number of examples exist for the latter, the knowledge about these mechanisms is much lower. Important differences between man and mouse regarding main immunological defense strategies are summarized in Fig. 1.

B. Response to Toll-like Receptor Ligands in Human and Mouse Blood

Recognition of pathogen- and damage-associated molecular patterns is important to minimize any threat to the host organism. Toll-like receptors (TLRs) as a prominent class of pattern recognition receptors activate the innate immune system by binding selected constituents of pathogenic microorganisms and of the damaged host tissue. Gram-negative bacteria are known to express lipopolysaccharide (LPS) that activates immune cells via TLR4 signaling. Other examples of TLR ligands are bacterial lipopeptides and lipoproteins, lipoteichoic acid, heat shock proteins, zymosan, flagellin, and double-stranded RNA from viruses. Up to now, 10 TLRs are known for humans and 12 for mice. Although many TLR-induced signaling pathways are highly conserved between man and mouse, there are a number of differences mostly related to TLR expression and ligand specificity. Important differences in TLR properties and signaling are summarized in Table 2.

In humans, TLR ligands cause an inflammation including sequelae during host protection against infections. A similar scenario occurs in noninfectious diseases where an inflammatory process is relevant, such as in arteriosclerosis, Alzheimer’s disease, and some forms of cancer. This kind of immune response corresponds to resistance, with the main aim to limit the burden of pathogenic microorganisms. In different human inflammatory scenarios, a common strategy of genetic responses under involvement of TLR signaling was recently reported.

In contrast to humans, mice are hardly challenged by TLR agonists. They developed tolerance strategies against the TLR4 agonist LPS, the TLR2 agonist peptidoglycan-associated lipoprotein, and other inflammatory agonists such as the superantigen staphylococcal enterotoxin B.
These immunological differences are further underlined by the noxious effect of LPS. In humans, a LPS dose of 2–4 ng/kg body mass induces fever and cytokines, and about 15 µg/kg causes already severe disease with shock. In mice, the median lethal dose is reported to be 10 mg/kg. Thus, LPS doses inducing severe disease with shock are several orders of magnitude higher in mice than in humans.

These effects were carefully evaluated by measuring cytokine release after challenging human and mouse blood with LPS or peptidoglycan-associated lipoprotein. When mouse serum was added to isolated human and mouse mononuclear cells it diminished the cytokine release more efficiently than human serum. Thus, mouse serum contains a yet unknown factor that is responsible for this effect. This factor was not inactivated by heat treatment but was sensitive to treatment with trypsin. Furthermore, mouse serum markedly reduced the mRNA encoded for tumor necrosis factor α (TNFα) in monocytes. However, mRNA expression of factors (e.g., MyD88s, SOCS1, SOCS3) which are known to limit TLR4 signaling and reduce TNFα production was not upregulated.

Due to the lack of clear data, it is only possible to speculate about the significance of this finding for the immunological response to LPS in mice. Maybe there are differential responses in various compartments in mice that would limit the appearance of a systemic inflammation due to suppressive activity of serum components from a local inflammatory event. An inverse correlation between LPS sensitivity and suppression of TNFα production was not only found for mouse serum but also for other animal sera. Hence, an appropriate model system for LPS sensitivity in human has to be chosen carefully.

C. Different Responses to Interferon γ

During inflammation, the cytokine interferon γ (IFNγ), released by specialized immune cells, is able to trigger innate immune response in humans and rodents. In mice, IFNγ induces the expression of 18 different genes of GTPases, the so-called p47 immunity-related GTPase (IRG) proteins. These proteins induce host response against bacterial and protozoan pathogens as shown by a dramatic increase in susceptibility to pathogens in IRG knockout mice.

One antimicrobial effect of IRG proteins in mice is the induction of autophagy of pathogen-loaded macrophages. This process does not require reactive oxygen and nitrogen species. Originally, autophagy has been described as a fundamental cellular adaptation to starvation in eukaryotes, whereby cells autodigest long-lived cytosolic macromolecules. Interestingly, several groups demonstrated that intracellular pathogens are also sequestered into autophagosomes, vacuoles with a characteristic double membrane, for degradation in autolysosomes. This autophagy process can be induced in murine mycobacterial-loaded macrophages by IFNγ. Thereby, the IRG protein LRG-47 is of importance stimulating the translocation of an autophagy factor (microtubule-associated protein 1A/1B-light chain 3) from the cytosol to the autophagosomal membrane promoting the maturation of mycobacterial phagosomes. The autophagic pathway overcomes the Mycobacterium tuberculosis induced phagolysosome biogenesis block.

Further, IRG proteins in mice induce vesiculation, destruction of Toxoplasma gondii parasitophorous vacuolar membranes, and modify lipid traffic in immune cells after escaping pathogens.

In striking contrast, humans express only two members of IRG proteins. None of the genes of this protein family are induced by IFNγ. Nevertheless, the human IRGM protein
participates in IFNγ-induced autophagy processes in human macrophages to eliminate intracellular mycobacteria. However, human IRGM does not display any additional antimicrobial activity.

General differences in human and mouse immune response also lead to different strategies of the pathogens to survive. In mice, IFNγ induces three different IRG genes for resistance against the primarily human pathogen *Chlamydia trachomatis*. Thereby, the IRG proteins trigger a rerouting of bacterial inclusions in mouse embryonic fibroblasts to autophagosomes. However, the mouse pathogen *Chlamydia muridarum* adapts to the autophagy process and blocks the interaction of IRG proteins with vacuole membranes.

In contrast, human cells resist *Chlamydia trachomatis* by expression of indoleamine 2,3-dioxygenase (IDO) in response to IFNγ or IFNγ+LPS. Thereby, IFNγ is of special importance as neither LPS nor *Chlamydia* alone is known to induce IDO. Indoleamine 2,3-dioxygenase causes a depletion of tryptophan that is necessary for pathogen growth. To overcome the lack of tryptophan, *Chlamydia trachomatis* expresses tryptophan synthase. Most mouse cell lines cope with *Chlamydia* or IFNγ stimulation by expression of inducible nitric oxide synthase (iNOS or NOS2) but do not express IDO. In human cells, iNOS is never induced by this pathogen or treatment with IFNγ. The outcome of NO, however, depends on the mouse cell line type. Further on, blockade of NO synthesis in mice only partially rescued *Chlamydia* growth indicating additive effects of NO to the antichlamydial activity of IRG proteins.

IV. SELECTED PROPERTIES OF INNATE IMMUNE CELLS

A. White Blood Cell Composition

In adult species, the balance between leukocytes in man and mouse is quite different. C57BL/6 mice contain 10–25% neutrophils, 75–90% lymphocytes, and about 2% monocytes. For CD-1 mice, 15–20% neutrophils (300–2000 cells/µL) and 50–70% lymphocytes (1000–7000 cells/µL) were reported.

In contrast, humans have 50–70% neutrophils (3500–7000 cells/µL) and 20–40% lymphocytes (1400–4000 cells/µL). The crucial role of neutrophils in humans is not only reflected in terms of quantity but also in the functional importance as described in the following section.

B. Neutrophil Granulocytes

Neutrophil granulocytes are the first cells accumulating at the inflammatory site from peripheral blood followed by monocytes. With the release of highly aggressive proteins and reactive metabolites they contribute to host defense. The most prominent task of neutrophils is the phagocytosis of bacteria. An uncontrolled activation can result in tissue injury. However, neutrophils are also important as regulators of inflammatory processes and are involved in acquired immunity by activation of T-cells, antigen presentation, or T-cell suppression.

1. Chemotaxis and Diapedesis of Neutrophils

During the course of inflammation, neutrophils are recruited from the peripheral blood to the site of inflammation by chemoattractants. In this process, differences between the human and murine system emerged. While interleukin (IL) 8 was identified as being the most important chemoattractant for human neutrophil recruitment, an orthologous counterpart is absent in mice. In contrast, mice express lungkine as attractant for
neutrophils in lung and other functional homologues of IL-8. Directional migration of neutrophils is furthermore stimulated by chemoattractive N-formylated peptides [with N-formyl-methionine-leucine-phenylalanine (fMLF) as prototype] that are formed, among others, by gram-negative bacteria. Only two formyl peptide receptors (FPR), FPR1 and FPR2, are expressed in human neutrophils. On the contrary, at least three members, Fpr1, Fpr2, and Fpr-s1 (also known as LXA4R), are expressed in murine neutrophils. However, their fMLF-affinity in comparison to the human FPR1 is low.

In the next step of leukocyte extravasation, rolling adhesion, further species-specific differences emerged. For instance, L-selectin from human but not from murine neutrophils binds to E-selectin. In addition, the treatment of mouse neutrophils with a protease mix eliminated the binding of P-selectin and E-selectin. However, on human neutrophils proteases abrogated only the P-selectin binding site, whereas E-selectin binding was only slightly affected. This might be attributed to cell-surface glycosphingolipids of human leukocytes as possible binding partners of E-selectin on endothelia cells. Furthermore, distinct glycosyltransferases synthesize E-selectin ligands in human and mouse granulocytes.

2. Granule Constituents in Neutrophils

Neutrophils are characterized by their microbicidal molecules packed in granules and released upon cell activation. Due to remarkable differences in expression and/or activity between man and mouse, particular attention has to be paid in research connected to neutrophil action. Differences are summarized in Table 3.

Prominent components of azurophilic granules in human neutrophils are defensins, small cysteine-rich cationic proteins that bind to microbial membranes and induce pore-like membrane defects. Three of the four human defensins in neutrophils (human neutrophil peptide HNP-1, HNP-2, HNP-3) account for 5–7% of total protein content and about 30–50% of protein content in azurophilic granules. In contrast, neutrophils from mice do not express defensins. In mice, Paneth cells, present in the crypts of the small intestine, express at least six different defensins, whereas in humans only two kinds of defensins (HNP-5, HNP-6) are found in these cells. Mouse defensins are processed by matrix metalloproteinase-7, while human defensins from Paneth cells are processed by trypsin.

Another member of the host defense peptides is the bactericidal/permeability-increasing protein (BPI). This cationic peptide fulfills antimicrobial activities by directly interacting with membranes of gram-negative bacteria, neutralizing the endotoxic effects of LPS by binding, and thereby contributing to phagocytosis by opsonizing bacteria. In humans, BPI is mainly expressed in neutrophils during the promyelocyte stage of differentiation and then stored in azurophilic granules. In mice, its expression pattern differs and under resting conditions BPI is mainly found in testis, epididymis, and only at low levels in myeloid cells.

Finally, one further key component of human neutrophils, the heme-containing enzyme myeloperoxidase (MPO) that is stored in large amounts in azurophilic granules of resting cells, differs in its expression between man and mouse. Myeloperoxidase is able to catalyze a wide range of one- and two-electron substrate oxidations. On the one hand, MPO contributes with special products to apoptosis induction in neutrophils and, thus, to termination of inflammatory response. On the other hand, MPO released from necrotic cells promotes an inflammation by recruiting neutrophils and chemical modification of proteins and other tissue constituents. The myeloperoxidase level in mice neutrophils is
about 10–20% that of human cells as determined by activity measurements.\textsuperscript{56,57} Differences exist also in the organization of the MPO promoter region between both species.\textsuperscript{58} Furthermore, lower levels of β-glucuronidase, lysozyme, and alkaline phosphatase were reported in mice neutrophils in comparison to human ones.\textsuperscript{57} In conclusion, the composition of granules significantly differs between human and mouse neutrophils. Various antimicrobial molecules, which contribute decisively to host defense in human neutrophils, are less abundant in mouse neutrophils.

\textbf{C. Eosinophil Granulocytes}

Eosinophil granulocytes constitute only 1–3% of the white blood cell count both in humans and mice. Upon production in bone marrow, they circulate in blood or, also despite absence of infection, reside in different organs (e.g., secondary lymphoid tissue, thymus, gastrointestinal tract) with so far unknown function. Eosinophils are specialized in host defense against parasites, but overwhelming activities have also been described in allergic response and asthma pathogenesis.\textsuperscript{59}

Interspecific varieties between human and murine eosinophils are only scarcely described. Nevertheless, differences exist in cell morphology (size, granularity), cell surface markers (e.g., Gr1 is only present in mice), mode of degranulation (compound and classical exocytosis are not observed in mice), and mediators released upon stimulation (eosinophil peroxidase is not released in mice upon fMLF, GM-CSF, PMA stimulation), as well as restricted expression of the chemokine eotaxin-3 to humans.\textsuperscript{60} The latter point is of importance especially in asthma research, as eotaxin-3, which is heavily expressed in lung epithelia, triggers a second phase of eosinophil migration in mild asthmatics.\textsuperscript{51,62} In mice, eotaxin-3 is only present as pseudogene and murine eosinophils do not respond to it.\textsuperscript{63} This suggests different roles of eotaxins in the pathogenesis of asthma.

\textbf{D. Monocytes and Macrophages}

Macrophages reside in virtually all tissue differentiated from circulating peripheral blood monocytes where they engulf apoptotic and necrotic cells as well as pathogens upon tissue damage or infection. In addition to their role as immune effector cell, macrophages are important for tissue homeostasis, antigen presentation, and immune regulation.\textsuperscript{64}

\textit{1. Subsets of Macrophage Activation}

Polarization of murine macrophages into M1 (classically activated) or M2 (alternatively activated) macrophages on the basis of gene expression profiles and identification of surface markers is often used to explore the different natures of macrophages, and a panel of markers exists for these subsets.\textsuperscript{65} This polarization was introduced to have clear parallels to T-helper cell functions. In human macrophages, the identification of M1 and M2 subsets is more challenging because of species-related differences in macrophage polarization markers. For example, the M2 mouse markers arginase 1, Relma (Fizz1), matrix metalloproteinase-1, and Chi3l3 (Ym1) are not expressed in humans, while Chi3l2 (Ykl39), fibrinoligase, and platelet-derived growth factor C are not found in mice.\textsuperscript{66}

\textit{2. Arginine Metabolism in Macrophages}

Great differences exist between human and murine macrophages in arginine metabolism. In mice, iNOS plays an important role in producing large amounts of NO and L-citrulline. The expression of this enzyme is upregulated by several orders of magnitude upon incubation of murine macrophages with LPS and IFN\textgamma.\textsuperscript{57} However, in human macrophages iNOS is not expressed and NO is not produced by these agents.\textsuperscript{55,68}
The lack of iNOS expression in human macrophages remains puzzling. There are discussions about dismissive factors in culture media and the lack of required epigenetic alterations.\textsuperscript{65} Murine macrophages are able to synthesize the iNOS cofactor tetrahydrobiopterin. This cofactor is not formed in human macrophages.\textsuperscript{69} Even the addition of this cofactor to isolated human macrophages did not induce NO production in stimulated cells.\textsuperscript{70}

Contrary, there are several reports about a strong expression of iNOS in human macrophages and other cells and an enhanced NO production in these cells under severe disease conditions.\textsuperscript{71–73} However, mechanisms for this iNOS activation remain unknown. Maybe other cytokines and cytokine combinations cause this activation of iNOS in human macrophages. For example, interferons $\alpha$ and $\beta$ are known to induce expression of iNOS in human macrophages. In contrast, murine macrophages are unable to produce NO in the presence of IFN$\alpha$. Further cytokine combinations known to produce NO in human macrophages are IL4+IFN$\gamma$ and IL-4+anti-CD23.\textsuperscript{72}

Arginine is also metabolized by arginase to L-ornithine and urea. In mice, cytoplasmic arginase type-1 is upregulated in alternatively activated macrophages. It antagonizes the activation of iNOS in classically activated macrophages.\textsuperscript{74} In this way, activation of arginase type-1 dampens tissue damage by pro-inflammatory agents associated with pro-inflammatory cytokines and iNOS activation but favors parasite survival and proliferation.\textsuperscript{75} In unstimulated murine leukocytes, there is no expression of arginase type-1. Contrarily in humans, the arginase type-1 is constitutively expressed in azurophilic granules of neutrophils, where it contributes to antimicrobial defense likely by arginine depletion in the phagolysosome.\textsuperscript{76} This arginase expression is insensitive to Th2 cytokines. In traumatic patients, expression of arginase type-1 is increased in mononuclear cells.\textsuperscript{77} This enzyme is not induced by IL-4 or IL-13 in human monocytes and macrophages in contrast to murine cells.\textsuperscript{78}

**E. Killing of Pathogenic Microorganisms**

In mice, several essential genes have been knocked out with the consequence of an impaired killing of selected pathogens.\textsuperscript{79} Knockout of phox components of NADPH oxidase is detrimental in both mice and humans. The corresponding human disorder is known as chronic granulomatous disease. These patients suffer similarly to the corresponding knockout mice from recurrent infections.\textsuperscript{80,81} In the case of myeloperoxidase, several adverse experimental scenarios with MPO-deficient mice have been described.\textsuperscript{82–84} Myeloperoxidase deficiency is common in humans but usually without serious problems. The only problem in human MPO deficiency concerns fungal infections in some immunosuppressive patients.\textsuperscript{85} Killing of *Candida albicans* is completely abolished by human neutrophils in the absence of MPO.\textsuperscript{85} In contrast, MPO-deficient mouse neutrophils exhibit a residual ability to kill this pathogen.\textsuperscript{83} Knockout mutations for elastase, cathepsin G, or inducible nitric oxide synthase also impaired the ability of these mice to deactivate a number of pathogens.\textsuperscript{79} For the human counterpart, any disease scenarios with primary deficiency of these enzymes are largely unknown.

Collectively, these examples evidence that in addition to the NADPH oxidase and myeloperoxidase pathway different synergistically acting components are involved in antimicrobial defense in human and murine phagocytes. While a broad range of small proteins, such as defensins and others, is characteristic of human leukocytes, nitrogen reactive species have a higher impact in microbe killing in mice.\textsuperscript{79,86} Especially the double iNOS and gp91phox knockout mouse is very susceptible to spontaneous infections.\textsuperscript{87}
F. Natural Killer Cells

Natural killer cells are lymphocytes of the innate immune system with both cytotoxicity and cytokine-producing effector function. They are able to destroy compromised host cells such as tumor cells and virus-infected cells limiting their spread and subsequent tissue damage. Although signaling pathways are largely conserved in human and murine killer cells, there are some differences in cell biology and receptor composition between both species.88,89

In mice, the activity of natural killer cells in spleen and blood is high at 4–10 weeks of age. In humans, their activity is relatively stable throughout the whole lifetime. In lung, mice have high activity of natural killer cells, whereas their activity is low in man. Expression of Fc-receptors on natural killer cells is much higher in humans than in mice.88

In mice, killer cells use Ly49 proteins as inhibitory receptors for major histocompatibility complex (MHC) I molecules. This protein family is absent in humans. Here proteins of the killer cell inhibitory receptor family, which is highly divergent to Ly49 proteins, are used as inhibitory receptors on the surface of natural killer cells.90

G. Mast Cells

Mast cells are large granulated cells which undergo their terminal stage of maturation after migration into vascularized tissues. Mast cells express IgE-specific Fc receptors (FcεR) on the cell surface. Upon stimulation and receptor cross-linking by immunoglobulin E and others, human mast cells release histamine, lipid mediators, cytokines, proteoglycans, and proteases. Histamine is released upon sensitization from mast cells in response to immunoglobulin E in humans. Although histamine is known to be present in mice blood and cell compartments, serotonin is responsible for physiological effects in anaphylactic reactions in this species.32 Murine mast cells contain significant amounts of serotonin, which is found only in few quantities in human mast cells.91

Production of TNFα dominates in murine mast cells, while human mast cells are an important source of IL-5, explaining the significant role of human mast cells during recruitment of eosinophils to sites of allergic inflammations. In contrast, murine mast cells resemble more human basophils. For example, IL-3 causes strong responses in murine mast cells and human basophils but only weak response in human mast cells. Murine mast cells and human basophils are also an important source of IL-4, whereas under normal conditions IL-4 is not produced by human mast cells. Furthermore, murine mast cells express CD14, like human monocytes, and various Toll-like receptors which are not, or only scarcely, found in humans.92

H. Ascorbic Acid and Urate

Inflammatory response and activation of immune cells are accompanied by an enhanced formation of reactive oxygen and nitrogen species that may contribute to tissue damage. Ascorbic acid and urate are important natural molecules with antioxidant properties.

Most rodents including mice and rats, but not guinea pigs, are able to synthesize ascorbic acid from glucose via a cascade of four subsequent enzyme reactions. In the last step, L-gulonolactone reacts with dioxygen to form ascorbic acid. This reaction is catalyzed by L-gulonolactone oxidase which is deficient in humans, other primates, and guinea pigs. In these species, the gene of this enzyme is present as a pseudogene.93 Thus, ascorbic acid is not synthesized in man and has to be taken up with food.
Surprisingly, tissue and blood levels of ascorbic acid are in the same range of order in healthy individuals of man and mouse. The status of ascorbic acid in tissues is determined by numerous factors such as expression of transporters, enzymatic reactions, and redox processes. Man and other mammals, which are unable to synthesize ascorbic acid, express the glucose transporter 1 together with stomatin in their erythrocytes and other cells. This unique transporting system mediates the cellular uptake of dehydroascorbic acid, the oxidized form of ascorbic acid. In cells, dehydroascorbic acid is rapidly reduced to ascorbic acid. In mice erythrocytes, there is no expression of glucose transporter 1 and no uptake of dehydroascorbic acid.

Despite protecting functions of iron-containing enzymes involved in synthesis of collagen, carnitine, and dopamine, ascorbic acid exhibits pronounced antioxidant functions in biological fluids. However, in humans urate has a higher impact on antioxidant defense reactions. The plasma concentration of this end product of purine metabolism exceeds by 160–450 µM that of ascorbic acid being around 60–80 µM in healthy individuals. Young wild-type mice have a urate level of about 60 µM in serum.

In mice, urate is further metabolized to (S)-allantoin via sequential conversion of urate catalyzed by urate oxidase, 5-hydroxyisourate hydrolase, and 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase. In humans, an active urate oxidase is absent because of nonsense mutations. The gene of 5-hydroxyisourate hydrolase is also inactive in humans, while the gene of the decarboxylase is apparently not expressed in the transcriptome.

The significance of the shift from ascorbate to urate in antioxidant defense during human evolution remains unknown. It is discussed that urate exhibits in addition to antioxidant properties also neuroprotective activities.

V. SELECTED DISEASE MODELS

A. Problems in Translation of Disease Data from Mouse to Man

1. Cancer Models

Mouse models of cancer contribute considerably to the knowledge of human cancer biology. Previous studies focused on implantation of human or syngeneic mouse tumor cells under the skin, into the abdominal cavity, or in the organ of origin of an immune-compromised mouse. These xenograft models are relative easy-to-use systems, but genetics and histology of these tumors are frequently not representative of the human ones. Nevertheless, recent advances were made in patient-derived xenografts representing clinical patient diversity. Increasing numbers of genetically engineered mouse models were developed in the recent years focusing on specific oncogene functions with reverse genetic approaches. These models are based on extensive techniques for genetic manipulation such as conditional and inducible gene targeting, chromosome engineering, or transgenic RNAi technologies. Also forward genetic approaches creating more phenotype-driven mouse models are available. For example, recombinant inbred mouse strains can be used to identify cancer-susceptibility genes. Also the transposon technique as a mobile genetic element is able to detect novel cancer genes. These valuable models allow detailed evaluation of mechanisms involved in tumor initiation, progression, and development as discussed in several recent reviews. However, there are still significant restrictions in the recapitulation of biological and clinical aspects of human cancers in mice. Clear species-specific differences between man and mouse exist. For instance, most mouse cells have active telomerase; therefore these cells are transformed more rapidly than...
human cells. Furthermore, mouse models tend to form relatively few spontaneous metastases or form metastases with divergent tissue specificity. Also drug metabolism and drug affinity to target proteins differ between mice and humans derogating the potential of mice as an effective drug testing model. Various mouse models possess genetic alterations in the germ line or notably in somatic cells representing the predisposition of human cancer rather than human sporadic cancer. Point mutations are typical of genetic alterations in human cancers. In contrast, overexpression or deletion of genes dominates in mouse models of cancer. Differences in the microenvironment of tumors and the host immune system are further important factors affecting de novo tumor development.

2. Autoimmune Disorders

Autoimmune disorders are usually induced by autoantigenes supplied either by active immunization using adjuvants or by infusion of previously activated lymphocytes. In mice, disease induction is highly artificial and therapeutic approaches start mostly before autoimmune challenge. In contrast, drug administration to autoimmune patients begins often after the autoimmune process has become chronic.

Induction of murine autoimmune encephalomyelitis is commonly applied to model myelin degeneration seen in multiple sclerosis. The protective effect of IFNγ in the mouse model failed in multiple sclerosis patients as IFNγ exacerbates the disease process. On the other hand, pharmacological blockade of interaction between the cellular adhesion molecules VLA4 and VCAM1 is helpful in both murine encephalomyelitis and multiple sclerosis patients.

For the therapy of autoimmune disorders, different approaches with antibodies against B-cell targets have been developed or are under intense investigation. For example rituximab, a specific anti-CD20 monoclonal antibody, efficiently diminished the titer of pathogenic autoantibodies in a mouse model of inflammatory arthritis. The majority of rheumatoid arthritis patients showed lower serum autoantibody level and clinical improvement under therapy with this drug. Nevertheless, there are a number of open questions around therapeutic use of rituximab. These open questions concern the long time to clinical response, the unsolved mechanism of action on B-cells, and the application to other autoimmune diseases.

3. Sepsis

In humans, the molecular picture of systemic inflammatory response and multiple organ dysfunction syndromes, known as “sepsis” syndromes, is very heterogeneous and the underlying mechanisms are still under debate. The sepsis syndrome is commonly associated with infection, inflammation, and complex activation of other protecting systems, but also especially at later stages, with suppressed immune functions, release of cytotoxic components, and organ failure. In severe cases, multiple organ dysfunctions, e.g., acute kidney injury, lead to a lethal outcome.

Several experimental approaches have been developed to induce sepsis in murine models. These approaches are the application of pathogenic bacteria and their products such as endotoxin infusion, as well as the disruption of protective barriers, as in the model of cecal ligation and puncture. Although these models reflect well some features of human sepsis, translation of their data is problematic. As outlined in Sec. III. B, mice are generally less sensitive to LPS than humans. Therapies with anti-TNFα or anti-IL1, which gave promising results in LPS-treated mice, did not improve survival of septic patients. In the murine model of cecal ligation and puncture, fecal material penetrates after colon...
perforation into the peritoneal cavity and triggers immune responses typical of human sepsis. However, this model fails to develop reproducible organ injury and the outcome of sepsis differs widely among laboratory mice. Often young, healthy mice are used in these studies. It is more realistic to use already sick animals when sepsis is induced. For example, mice with restricted kidney function developed more severe sepsis.

Pathogenesis of sepsis is connected to nitric oxide metabolism, a critical regulator of vasodilation and vascular homeostasis, but it interferes also with cellular oxygen utilization and the excessive formation of oxidants, thereby stimulating an inflammation. Interestingly, in septic mice, a much higher plasma level of nitric oxide metabolites is observed than in septic patients, indicating that mice are more resistant to pathological NO effects.

A further important factor contributing to organ dysfunction in severe sepsis is an excessive intravascular hemolysis. Plasma levels of haptoglobin and hemopexin, which both bind and remove free hemoglobin and heme, respectively, from circulation, are similar in healthy humans and mouse. Both proteins rapidly drop down by excessive release of hemoglobin from red blood cells. Moreover, free hemoglobin efficiently scavenges nitric oxide and limits, thus, the bioavailability of NO. A connection between the different role of NO in the sepsis of humans and mice and the scavenging of NO by free hemoglobin after excessive hemolysis could be assumed but is unproven so far.

4. Asthma
A further complex inflammatory disease where mice are widely used as animal model is asthma. In mice, antibodies against IL-5 successfully diminished the airway hypersensitivity caused by infiltrated eosinophils in an experimental model of asthma. In contrast, therapeutic application of anti-IL-5 failed in asthmatic patients in effects on late asthmatic response and airway hyper-responsiveness despite the pronounced decrease of blood and sputum eosinophils. Apparently, the interplay between various immune cells such as T-cells, eosinophils, mast cells, and others is crucial for late asthmatic reactions. While plasma exudation dominates in bronchial asthma and allergic rhinitis in humans, only little plasma exudation is observed in mouse airways. Distribution and properties of eosinophils differ also in human and murine asthma. While human eosinophils release their constituents at inflammatory sites, the mouse counterpart is resistant to degranulation.

5. Atherosclerosis
Atherosclerosis is a very common disorder in humans. Oxidative modification of lipoproteins and their uncontrolled uptake by macrophages play a key role in atheroma development. However, their exact molecular mechanisms and regulatory aspects are only poorly understood. Human atherosclerotic lesions contain active myeloperoxidase and the myeloperoxidase product chlorotyrosine, indicating the involvement of phagocytes in atheroma formation. Interestingly, myeloperoxidase-deficient individuals developed less pronounced cardiovascular problems than normal persons. Mice are characterized in comparison to humans by a dominance of high-density lipoproteins over pro-atherogenic low-density lipoproteins and by differences in expression and regulation of genes that control lipoproteins. For example, humans but not mice express in their blood the cholesterol ester transfer protein that facilitates the transfer of cholesteryl esters between lipoproteins. As wild-type mice are highly resistant to the development of atherosclerosis, different knockout and transgenic mouse strains (such as apolipoprotein E-deficient mice, low-density lipoprotein receptor-deficient mice, or ApoE*3-Leiden transgenic mice) are...
routinely applied in experimental atherosclerosis research. In atherogenic lesions of the low-density lipoprotein receptor knockout mice, no active myeloperoxidase and chlorotyrosines were detected. Additional MPO deficiency enhanced the atherosclerotic process. Otherwise, mice deficient for the low-density lipoprotein receptor and additionally transgenic for the human myeloperoxidase gene developed increased atherosclerotic lesions. Thus, different molecular processes dominate in plaque formation in humans and mice.

B. Differences in Response to Disease Inducers between Mouse and Man

In humans, there were similar genetic responses between burn and trauma patients despite the large heterogeneity in trauma patients concerning demographic aspects, degree of injury, variable amounts of blood received by infusion, and different drug therapies. There was also a sufficient correlation in genetic response between injured patients and patients severely affected by bacterial endotoxins. These data support activation of common immune mechanisms in severe inflammatory diseases in humans. In contrast, there was no correlation in genetic response to the corresponding mouse models for burn, trauma, or endotoxinemia. There was also no correlation between these different mouse models.

In this investigation, great differences were also found in activated and depressed pathways between both species. In humans, Fc-receptor-mediated phagocytosis by mononuclear cells, signaling via TLRs, IL-10, integrins, or B-cell receptors were much more activated than in affected mice. Several pathways in T-cells were drastically depressed in human diseases (e.g., iCOS-iCOSL signaling in T-helper cells, calcium-induced T-lymphocyte apoptosis, T-cell receptor signaling), whereas much smaller or no effects were observed in mice models.

C. The Humanized Mouse

In order to overcome the obstacles between the different immunological responses of man and mouse, humanized mice were created. These are immunodeficient mice where human cells have been introduced. By this approach, mice with human immunological properties were generated. There are four different models utilized in engraftment of the human immune system into mice, in which either human peripheral blood lymphocytes or human hematopoietic stem cells (HSC) were injected into mice blood and tissue, or where fetal liver and thymus fragments were implanted under the renal capsule in mice.

Immunodeficient mice with a mutation in the γ-chain of the IL-2 receptor (IL2rγ) facilitate considerably the engraftment of human hematopoietic stem cells. Thus, these mice allow studies on human immune cells, including T- and B-cells.

Major disadvantages of the early humanized mouse models were due to species-related differences of cytokines and growth factors and the presence of mouse MHC molecules instead of the human leukocyte antigen (HLA) system. Furthermore, humanized immunodeficient Rag2−/−IL2rγ−/− mice strains still possess an intact mouse myeloid compartment, which might contribute to a low rate of human myeloid cell reconstitution in humanized mouse. In addition, engraftment of mice with human stem cells is only transient, not lifelong, probably due to inefficient integration and levels of HSC decline after 4–6 months in the xenogeneic environment. Furthermore, the transplantation rates differ, even when the same HSC donor is used.
Various technological approaches try to overcome these problems by developing the “next-generation” immunodeficient IL2rγ−/− mice by expressing human transgenes and the targeted inactivation of mouse genes important for the innate immune system.

For instance, Rongvaux et al. replaced the thrombopoietin gene by its human counterpart in Rag2−/−IL2rγ−/− mice. Thrombopoietin has been previously recognized as a cytokine that supports self-renewal and maintenance of HSC. In the knock-in technology it led to a multilineage differentiation of hematopoietic cells with an improved ratio of granulocytes to lymphocytes, thereby better reflecting human physiological conditions in the bone marrow. Further on, maintenance of CD34+ hematopoietic stem and progenitor cells as well as engraftment levels were improved. As a side effect of gene replacement, thrombocytopenia developed. Since thrombopoietin is crucial for platelet development, reduced levels or an altered biological activity of the humanized variant were not sufficient to contribute to thrombopoiesis in the xenogenic model system.

Considering the mismatch of MHC molecules on mice and human immune cells, a severe response in the form of a xenogenic graft-versus-host disease can develop. It results from the action of cytotoxic T-cells directed against mouse MHC molecules. This mismatch in MHC molecules, further on, contributes to an impaired T-cell function as well as limited immunoglobulin class switching by human B-cells. To overcome these problems, mice transgenic for the human leukocyte antigen (HLA) were generated. For instance, transgenic expression of the HLA class II molecule DR4 in Rag2−/−IL2rγ−/− mice infused with HLA-DR-matching HSC favored homing and development of T-cell precursors in thymus, promoted further T-cell repopulation in the periphery, and developed functional CD4 and CD8 T-cells. Moreover, those mice developed functional B-cells able to reconstitute immunoglobulin M levels comparable to humans and to undergo immunoglobulin class switching.

Besides the achievements gained in the last years, several limitations of the next-generation humanized mice still exist. Firstly, the expression of human immune factors in immunodeficient mice has the disadvantage that many human factors cross-react with mouse cells with the possible consequence of unexpected phenotypic changes. Secondly, lymphoid reconstitution in engrafted mice is challenging. Even though the mesenteric lymph nodes develop, the organization and size of the peripheral lymph nodes is less sufficient.

A further impairment of the humanized mouse is the inability of human granulocytes, platelets, and red blood cells to circulate appropriately in the peripheral blood of the murine host, although progenitors of these cells are detected in bone marrow. It is assumed that circulating human cells are removed by murine macrophages. In humanized mice, the administration of granulocyte colony-stimulating factor led to an improved mobilization of mature human neutrophils into peripheral blood. Subsequent LPS administration resulted in a robust neutrophil effector function in vitro. In another study, the in vivo administration of granulocyte colony-stimulating factor led to an enhanced circulation of human myeloid cells. However, the number of neutrophils detected in both studies in the periphery is still not comparable to human physiological conditions.

In recent years, multiple approaches were developed to construct a humanized mouse model. This enables researchers to penetrate much deeper into specific human pathologies and to create more detailed models for diseases. Although these approaches were mainly directed to evaluate details of the adaptive immune system, their further
improvement will also include studies on human innate cells. Nevertheless, it becomes obvious that these studies are useful to investigate a clear mechanistic question rather than to examine the complete human immune system.152,154

VI. CONCLUSIONS

After being divided about 90 million years ago, independent development started for the mouse and human lineages. Organization of the immune system differs considerably between both species. The considerably longer lifespan of man versus mouse is assumed to be a trigger to ensure an efficient control over pathogens by the human immune system. In defense against invading microorganisms, resistance mechanisms dominate in humans, while tolerance determines the immune response in mice.12,13 Species differences exist in activation and function of effector molecules released by immune cells to control pathogens. Accordingly, the human immune system is highly susceptible to Toll-like receptor agonists in contrast to the murine system.17 Different pathways are also initiated in response to IFNγ. In man, tryptophan depletion via enhanced expression of IDO is induced by IFNγ, while IRG proteins are expressed and autophagy of pathogen-loaded cells is induced in mice.24 Furthermore, a number of pathogens are predominantly found in humans but not, or seldom, in mice. To these pathogens belong *Mycobacterium tuberculosis*, *Mycobacterium leprae*, *Shigella flexneri*, *Plasmodium falciparum*, and viruses such as measles and dengue virus.65 Importantly, a common strategy against pathogens, traumata, and antigens can be evaluated in humans but not in mice.15

Different strategies in immune response are also reflected in the composition and properties of leukocytes. A higher number of neutrophils are characteristic of human blood. These neutrophils contain more antimicrobial components than murine cells. Activated murine macrophages enhance considerably the expression of inducible NO-synthase and arginase, a property that is only scarcely found in human macrophages. Histamine is released from human mast cells, while serotonin is liberated from these cells in mice.

Several consequences arise from the existence of different principal mechanisms to combat infections in man and mouse blood. In humans, sepsis and autoimmune disorders might develop and lead to numerous complications. It is very hard to induce such disease scenarios in more tolerant mice. Here it is necessary to provide additional genetic manipulations to alter host response and to induce secondary inflammation. Thus, the value of mice models for human diseases with inflammatory pathogenesis is limited. Drugs are known to act mostly via distinct molecular mechanisms. Thus, investigation by animal models is mainly directed to evaluate these mechanisms. As the main immune mechanisms in mice are quite different to humans, it is necessary to develop synthetic human models for investigations of disease-mediated alterations in cells and tissues as well as to extract information from personal genomes.

Taken together, these differences in organization of the immune system greatly disturb direct translation of data from murine disease models to human pathologies. Thus, it is not surprising that in many cases promising therapeutic principles found in mice models do not work in humans. In each case, it must be carefully considered which individual aspects can be similarly reflected in both species and where differences in pathways, protein expression, sensitivity of initiating agents, and others make a direct translation impossible.
Acknowledgments

The authors gratefully acknowledge the financial support provided by the Sächsische Aufbaubank from a funding of the European Regional Development Fund (ERDF) (SAB Project no. 100116526) and the German Federal Ministry of Education and Research (BMBF 1315883).
Figure and Tables

**Figure 1:** Important differences between mouse and man in immunological defense strategies.

<table>
<thead>
<tr>
<th>resistance induction</th>
<th>tolerance induction</th>
</tr>
</thead>
<tbody>
<tr>
<td>common strategy against (non-)infectious stimuli</td>
<td>no common strategy against (non-)infectious stimuli</td>
</tr>
<tr>
<td>~ 10-15 µg LPS/kg induce shock</td>
<td>~ 10 mg LPS/kg induce shock</td>
</tr>
<tr>
<td>no expression of iNOS + arginase in macrophages</td>
<td>strong expression of iNOS + arginase in macrophages</td>
</tr>
<tr>
<td>IFNγ induces IDO expression + Trp depletion</td>
<td>IFNγ induces IRG expression + autophagy</td>
</tr>
</tbody>
</table>

**Table 1:** Main differences between human and mouse genomes

<table>
<thead>
<tr>
<th>Genome characteristics</th>
<th>Humans</th>
<th>Mice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of genes</td>
<td>19,042</td>
<td>20,21</td>
</tr>
<tr>
<td>Functionally related genes</td>
<td>15,187</td>
<td>15,18</td>
</tr>
<tr>
<td>Percentage of orthologous genes</td>
<td>80%</td>
<td>75%</td>
</tr>
<tr>
<td>Gene duplicates</td>
<td>2941</td>
<td>376</td>
</tr>
</tbody>
</table>
### Table 2: Differences in Toll-like receptor properties and signaling between man and mouse

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Property</th>
<th>Humans</th>
<th>Mice</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>TLR2</td>
<td>Expression in thymus and T-cells</td>
<td>No</td>
<td>Yes</td>
<td>164</td>
</tr>
<tr>
<td>TLR2</td>
<td>Expression on circulating leukocytes</td>
<td>Expressed</td>
<td>Poorly expressed</td>
<td>164</td>
</tr>
<tr>
<td>TLR2</td>
<td>Recognition of <em>Aspergillus fumigatus</em> by heterodimers with other TLRs</td>
<td>Heterodimers with TRL1, but not TRL6</td>
<td>Heterodimers with TRL1 and TRL6</td>
<td>165</td>
</tr>
<tr>
<td>TLR2</td>
<td>Recognition of tri-lauroylated lipopeptides</td>
<td>No</td>
<td>Yes</td>
<td>166</td>
</tr>
<tr>
<td>TLR3</td>
<td>Stimulation of dendritic cells and macrophages by polyinosinic-polycytidylic acid</td>
<td>No activation of NFκB and MAPK; no production of TNFα and IL-6</td>
<td>Activation of NFκB and MAPK; production of TNFα and IL-6</td>
<td>167</td>
</tr>
<tr>
<td>TLR3</td>
<td>Effect of LPS and IFNβ</td>
<td>LPS prevents IFNβ-mediated upregulation of TLR3</td>
<td>LPS mediates upregulation of TLR3 via IFNβ</td>
<td>168</td>
</tr>
<tr>
<td>TLR4</td>
<td>Recognition of taxol or LPS from <em>Leptospira</em></td>
<td>No</td>
<td>Yes</td>
<td>169,170</td>
</tr>
<tr>
<td>TLR4</td>
<td>Cytotoxic effects of LPS</td>
<td>At low doses</td>
<td>At high doses</td>
<td>17,18,19–23</td>
</tr>
<tr>
<td>TLR5</td>
<td>Recognition of flagellins</td>
<td>More sensitive against most flagellins compared to human TLR5</td>
<td>171</td>
<td></td>
</tr>
<tr>
<td>TLR7/8</td>
<td>Activation by single-stranded RNA</td>
<td>By TLR8</td>
<td>By TLR7</td>
<td>172</td>
</tr>
<tr>
<td>TLR8</td>
<td>Activation by antiviral compound R848</td>
<td>Yes</td>
<td>No</td>
<td>173</td>
</tr>
<tr>
<td>TLR10</td>
<td>Response to viral components</td>
<td>Yes</td>
<td>Pseudogene</td>
<td>174</td>
</tr>
<tr>
<td>TLR11</td>
<td>Recognition of profilin</td>
<td>Pseudogene</td>
<td>Yes</td>
<td>175</td>
</tr>
<tr>
<td>TLR12</td>
<td>Recognition of profilin</td>
<td>Gene not present</td>
<td>Yes</td>
<td>175</td>
</tr>
<tr>
<td>TLR13</td>
<td>Gene not present</td>
<td>Gene not present</td>
<td>176</td>
<td></td>
</tr>
</tbody>
</table>

### Table 3: Differences in expression and properties of granule constituents in neutrophils in man and mouse

<table>
<thead>
<tr>
<th>Granule expression of</th>
<th>Humans</th>
<th>Mouse</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Defensins</td>
<td>Strong</td>
<td>Absent</td>
<td>48,49</td>
</tr>
<tr>
<td>BPI</td>
<td>Strong</td>
<td>Poor</td>
<td>55</td>
</tr>
<tr>
<td>MPO</td>
<td>Strong</td>
<td>Poor</td>
<td>56,57</td>
</tr>
<tr>
<td>β-Glucuronidase</td>
<td>Strong</td>
<td>Poor</td>
<td>57</td>
</tr>
<tr>
<td>Lysozyme</td>
<td>Strong</td>
<td>Poor</td>
<td>57</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>Strong</td>
<td>Poor</td>
<td>57</td>
</tr>
<tr>
<td>Arginase type-1</td>
<td>Constitutively</td>
<td>Only after stimulation</td>
<td>76</td>
</tr>
</tbody>
</table>
References


